Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2021.5992
Abstract: Importance Junctional epidermolysis bullosa (JEB) is an incurable blistering skin disorder with high infant mortality often caused by nonsense variants in the genes that encode laminin 332. Objective To evaluate the safety and outcomes following… read more here.
Keywords: treatment patients; epidermolysis bullosa; nonsense variants; laminin 332 ... See more keywords
O09 Drug delivery kinetics of intravenous gentamicin in a population of neonates
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2019-esdppp.9
Abstract: Background Gentamicin is commonly used in the NICU setting and is often administered via long lines, which increases variability in the rate of administration. We aimed to model drug delivery pharmacokinetic parameters for intravenous gentamicin… read more here.
Keywords: delivery kinetics; drug delivery; delivery; intravenous gentamicin ... See more keywords